Tourette Syndrome Treatment Market, by Drug Class (Antiadrenergic Agents, Antipsychotic Agents, Atypical Antipsychotics, Carbonic Anhydrase Inhibitor Anticonvulsants, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2026

Tourette syndrome is a rare and severe neurological disorder which causes tics. Tic is a repetitive involuntary movements, sudden, no rhythmic motor movements. It occurs due to the mutations of the SLITRK1 gene, which plays an important role in development of nerve cells. This syndrome usually occurs among the people of age between 2-15 years. There are four types of tics: motor tics (uncontrolled body movements), vocal tics (outburst of sound), simple tics (includes few parts of body) and complex tics (contains several parts of body). Tourette’s syndrome is related to other additional neurobehavioral problems like impulsivity, problems with reading and writing, obsessive compulsive symptoms. It can be treated with neuroleptics; haloperidol and pimozide are largely used medicines for Tourette syndrome. Other medications such as guanfacine and clonidine are useful to treat the severity of tics.

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/2642

Tourette Syndrome Treatment Market Drivers

Drug approvals by regulatory authorities is expected to boost the global tourette syndrome treatment market growth. For instance, in October 23, 2017, Neurocrine Biosciences Inc. announced that the Food Drug and Administration approved valbenazine orphan drug designation to treat the pediatric patients with the Tourette syndrome. Furthermore, in September 19, 2017, Teva Pharmaceutical Industries and Nuvelution Pharma announced their partnership to develop AUSTEDO (deutetrabenazine) tablets for the treatment of tics which is associated to tourette syndrome in pediatric patients in the U.S. This partnership will drive the development of Austedo (deutetrabenazine) in Tourette syndrome by bringing new treatment options more quickly which are more necessary for the affected young patients. These factors are expected to propel the global Tourette syndrome treatment market growth.

Moreover, there are several investigations made for the treatment of Tourette syndrome. For instance, in March 2019, Wesley Medical Research was partnering with the University of Sydney in Australia which carried the clinical trial to investigate whether the medical cannabis could be used to treat the individuals with Tourette syndrome. This trial will help examine efficacy and safety of cannabinoids on tic frequency as well as the psychiatric symptoms associated with Tourette syndrome.

Furthermore, the acquisitions of companies drive the growth of the Tourette syndrome treatment market. For instance, on August 14, 2018, Emalex Biosciences acquired the Psyadon Pharmaceuticals and the rights to develop, register and market ecopipam, the investigational drug of Psyadon Pharmaceuticals, which is used to treat the Tourette syndrome in children less than 16 years of age.

Browse Research Report: https://www.coherentmarketinsights.com/ongoing-insight/tourette-syndrome-treatment-market-2642

Tourette Syndrome Treatment Market Regional Analysis

On the basis of region, the Tourette syndrome market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the Tourette syndrome treatment market due to presence of large number of key players like Otsuka Holdings Co., Ltd, AstraZeneca PLC, Catalyst Pharmaceutical Parteners, Inc. In terms of revenue, U.S. contributes the major share of this syndrome treatment market. According to the National Institute Of Neurological Disorders And Stroke(NIH), it is estimated that around 2,00,000 Americans have the most severe form of Tourette syndrome and as many as one in 100 shows milder or less complex symptoms such as vocal tics.

Tourette Syndrome Treatment Market Restraints

Withdrawal of the drugs in late stages of clinical trials has hampered the global Tourette syndrome treatment market growth. For instance, on December 12, 2018, Neurocrine Biosciences revealed that the phase IIb study of valbenazine did not meet the primary endpoint of reducing the tic severity in young people in moderate to severe form of diseases.

Tourette Syndrome Treatment Market Key Players

Some of the major players operating in the global Tourette syndrome treatment market include Neurocrine Biosciences Inc., Novartis AG, Otsuka Pharmaceutical Co., Ltd., Apotex, Inc., Janssen Pharmaceuticals, Inc., Teva Pharmaceuticals, Zydus Pharmaceuticals, Torrent Pharmaceuticals Limited and Eli Lilly Pharmaceuticals.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/2642

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
mailto:[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737